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ABSTRACT
Objective: Felodipine (FD) is an effective Biopharmaceutics Classification System Class II calcium channel blocker mainly used in the management of 
hypertension and angina pectoris. It has poor solubility and low oral bioavailability (15%). To overcome these disadvantages and to maintain constant 
plasma concentration for maximum therapeutic activity, there is a need to design an alternative route, that is, transdermal route. The pharmacokinetic 
parameters make FD a suitable candidate for transdermal delivery. The present investigation consists of the study of in vitro and ex vivo skin flux of 
FD from bilayered transdermal patches. 
Methods: The patches were fabricated by solvent casting method using hydrophilic and hydrophobic polymer with different composition. Tween 
80 incorporated as solubilizer, polyethylene glycol 600 as plasticizer, menthol, eucalyptus oil, and lemongrass oil used as permeation enhancers, 
respectively. The prepared transdermal drug delivery system was extensively evaluated for in vitro release, ex vivo permeation through pig ear skin, 
moisture content, moisture absorption, water vapor transmission, and mechanical properties. The physicochemical interaction between FD and 
polymers was investigated by Fourier-transform infrared (FTIR) spectroscopy. 
Results: All the formulations exhibited satisfactory physicochemical and mechanical characteristics. A flux of 35.2 µg/cm2 h, 27.9 µg/cm2 h, and 
25.25 µg/cm2 h was achieved for optimized formulations containing lemongrass oil, eucalyptus oil, and menthol, respectively, permeation enhances. 
Values of tensile strength (0.0652±0.034 kg/mm²) and elongation at break (0.8749±0.0.0029% mm²) revealed that formulation F9 was strong but not 
brittle. Drug and excipients compatibility studies showed no evidence of interaction between the active ingredient and polymers.
Conclusion: Bilayered FD transdermal patches could be prepared with required flux and suitable mechanical properties.
Keywords: Felodipine, Bilayered transdermal patches, Permeation enhancer, In vitro release, Ex vivo permeation, Flux.
INTRODUCTION
Felodipine (FD) is a dihydropyridine calcium channel blocker mainly 
used to treat high blood pressure and angina pectoris [1]. It is rapidly 
absorbed after oral administration but it undergoes extensive first-
pass hepatic metabolism, leading to poor bioavailability of 15% [2]. 
The low oral bioavailability confines its use, thus an alternative route 
of administration is desirable to deliver high concentration in blood to 
treat management in hypertension and angina. 
Among the various routes of novel controlled drug delivery systems, 
transdermal route is most preferred route for low bioavailability drug, 
thus achieving the systemic effect. Transdermal drug delivery system 
(TDDS) is self-contained discrete dosage form when which applied to the 
skin it delivers drug through the skin at controlled rate to the systemic 
circulation [3]. Its potential advantage is overcoming hepatic first pass 
metabolism thereby increasing bioavailability of the drug molecule [4]. 
Moreover, it provides convenient, painless self-administration, 
termination of drug action is possible in case of any toxicity reactions are 
occurred. Greater patient compliance due to avoiding multiple dosing, it 
also provides constant and prolonged drug levels in plasma [5,6]. 
From both physicochemical (low molecular weight 384.25 g/mol, 
low dose 10 mg) and pharmacokinetic (absolute bioavailability about 
15% and log P, 1–3), FD was considered to be a suitable candidate for 
transdermal delivery [7]. Physical techniques such as iontophoresis, 
electroporation, sonophoresis, and microneedles and chemical 
penetration enhancers such as solvents, surfactants, fatty acids, and 
terpenes are used to increase transdermal permeation rate. In the 
present investigation, menthol, eucalyptus oil, and lemongrass oil are 
used as permeation enhancers. In the initial trials which were made 
with monolayer patches, drug shows precipitation in primary layer. 
To avoid this precipitation, bilayered matrix transdermal patches were 
developed. The objective of the present investigation was development 
of bilayered transdermal therapeutic system for FD and to evaluate 
physicochemical, mechanical properties, in vitro release, and ex vivo 
permeation through pig ear skin [8-10].
METHODS
Materials
FD is a gift sample from Hetero Labs, Hyderabad. Hydroxypropyl 
methylcellulose (HPMC) E15 and Eudragit RL PO procured from 
Qualikems Fine Chem. Pvt. Ltd. Polyethylene glycol (PEG) 600, methanol, 
and dichloromethane (DCM) were of analytical grade purchased from 
Research-Lab Fine Chem. Industries, Mumbai. Menthol, eucalyptus oil, 
and lemongrass oil were obtained from SD Fine Chemicals, Maharashtra, 
India.
Methods
Development of bilayered transdermal systems
Bilayered matrix type transdermal patches were prepared by solvent 
casting method with different ratios of HPMC E15 as primary polymeric 
layer, Eudragit RL PO as secondary polymeric layer, primary polymer 
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was added to 20 ml of solvent mixture (DCM and methanol, 1:1) and 
allowed to stand for 6 h to swell. Small amount of polymer was added 
to solvent mixture to prevent the lumps. Weighed accurate amount of 
FD was dissolved in 5 ml of solvent mixture and added to the polymeric 
solution and mixed thoroughly to get uniform solution. Polyethylene 
glycol 400 was added to polymer mixture as a plasticizer and vortex for 
5 min. The total polymer mixture was set aside for 10 min to remove 
entrapped air, then transferred to Petri plate. Then, secondary polymeric 
solution was prepared by dissolving required quantity of Eudragit RL 
PO and required amount of PEG 600 in 15 ml of solvent mixture and 
poured over the primary layer which is present in Petri plate and allowed 
to dry at room temperature. One funnel was placed over the Petri plate 
in inverted position to control the rate of evaporation of solvent. The 
developed patches were removed carefully, cut into required size (3.14 
cm²), and stored in desiccators for further studies. Patches containing 
penetration enhancers (1% v/v) menthol, eucalyptus oil, and lemongrass 
oil were also prepared in the same method explained above by adding 
permeation enhancer with required amount to the polyethylene glycol 
and then mixed with polymeric solution [11-14]. Fabrication method and 
composition of details of patches are shown in Table 1.
Evaluation of physicochemical parameters
Six films from each formulation weighed individually and average weight 
was calculated. Thickness of the patch was measured at six different 
points of patch using screw gauge. Patches from each formulation were 
taken and cut into 4 cm² pieces and weighed. The pieces were taken into 
100 ml volumetric flask, dissolve the patch in 2 ml of solvent mixture 
(methanol:DCM) make up to 100 ml with pH 6.8 phosphate buffer. The 
above solution was filtered using 0.45 µm membrane filter and drug 
content was analyzed using ultraviolet (UV)–visible spectrophotometer 
at 364 nm. The folding endurance was determined manually by folding 
a small strip of the patch repeatedly at the same place until it was broke. 
The number of the times the strip could be folded at the same place 
without breaking gave the folding endurance [15,16].
Moisture absorption
The patches were weighed accurately and placed in desiccators 
containing 100 ml of saturated solution of aluminum chloride, which 
maintains 79.5% relative humidity (RH), after 3 days, the patches were 
taken out and weighed. The percentage of moisture absorption was 
calculated as difference between final and initial weight of the patch 










Transdermal films were weighed accurately and placed in desiccators 
containing calcium chloride for 24 h at 40°C. The final weight was noted 
until there was no further increase in patch weight. The percentage of 
moisture content was calculating by the following formula.





Water vapor transmission rate (WVTR)
It was performed according to method described by use glass vials 
of equal diameter transmission cells. One gram of calcium chloride 
placed in the cell and the patch was fixed on to the brim. The cells were 
accurately weighed and placed in a desiccators containing potassium 
chloride to maintain a RH 84%. The cells were taken out and weighed. 
Water vapor transmitted calculated by the following formula.









Mechanical properties of the patches were tested using a 
microprocessor-based advanced force gauze (Ultra Test, Mecmesin, 
UK) equipped with a 25 kg load cell. The dimensions of film strip were 
60×10 mm and free from air bubbles or physical imperfections were 
pulled with strips to a distance held between two clamps positioned 
at a distance of 3 cm during measurement the clamp at a rate 2 mm/
still the transdermal film broke the force and elongation was measured, 
when the film broke. The mechanical properties calculated by the 
following formulae [17].
Force at break(kg)








( ) = ××
Increase in length 100






In vitro drug release studies
In vitro drug release studies are carried out using unique selling 
proposition -type 5 apparatus (paddle over disc method). The disc 
assembly holds the transdermal system at the bottom of the vessel. 
The temperature is maintained at 32°C±0.5. A distance between 
the paddle blade and surface of the disc assembly is 25 mm which 
should be maintained during the test. The vessel containing 900 ml 
of phosphate-buffered saline (PBS) of pH 6.8 containing 15%v/w of 
PEG and stirred at 25 rpm. One milliliter of samples was withdrawn 
at predetermined time intervals, replaced with equal volume of fresh 
medium. The drug content in the samples was determined by UV–visible 
Table 1: Composition of bilayered transdermal patches
Primary layer
Ingredient/code F1 F2 F3 F4 F5 F6 F7 F8 F9
Felodipine (mg) 155 155 155 155 155 155 155 155 155
HPMC E15 (mg) 775 930 1085 1240 1395 1550 930 930 930
PEG 600 (mL) 155 186 217 248 279 310 186 186 186
Menthol (mL) - - - - - - 9.36 - -
Eucalyptus oil (mL) - - - - - - - 9.36 -
Lemongrass oil (mL) - - - - - - - - 9.36
Tween 80 (mL) - - - - - - 200 200 200
Methanol (mL) 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5
DCM (mL) 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5
Secondary layer 
Eudragit RL PO (mg) 300 300 300 300 300 300 300 300 300
PEG 600 (mL) 155 186 217 248 279 310 186 186 186
Methanol (mL) 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5
DCM (mL) 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5
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spectrophotometer at 364 nm. Cumulative amount of drug released 
was calculated and plotted against time [18-20].
Ex vivo drug release studies
Preparation of pig ear skin
Pig ear was obtained from slaughter house. The hair of pig ear skin was 
trimmed short (>2 mm) with a pair of scissors, prepared the epidermis 
of pig ear skin surgically by heat separation technique. Involving 
soaking the entire pig ear skin in water at 60°C for 45 s and followed 
by careful removal of epidermis. The epidermis was washed with water 
and used for the ex vivo skin permeability studies. 
For ex vivo studies, the skin was mounted between the two compartments 
of Franz diffusion cell with facing stratum carenum donor compartment 
a dialysis membrane (HiMedia M.W cutoff 5000) placed over the patch, 
to secure it tightly in the way that it will not get dislodged from the skin, 
the receiver phase contained 20 ml PBS of pH 6.8 containing 15% v/v 
PEG which was stirred at 500 rpm on a magnetic stirrer and the whole 
assembly was kept at 37±0.5°C. Samples of 1 ml were withdrawn at pre-
determined time intervals up to 24 h, then replace the equal volume of 
fresh medium and analyzed using UV–visible spectrophotometer at 364 
nm. Cumulative amount of drug permeated in µg/cm² plotted against time 
and drug flux (µg/h/cm²) at steady state was calculated by dividing the 
slope of linear portion of the curve by the area of skin surface (3.14 cm²) 
and the skin permeability coefficient was reduced by dividing the initial 
drug load. The targeted flux was calculated by the following formula [21].




Drug polymer interaction studies
Fourier-transform infrared (FTIR) spectroscopy studies were carried 
out to determine possible interaction studies between drug and 
polymer utilizing the KBr pellet method (PerkinElmer FT-IR). 
Release kinetics 
Data of in vitro release were fit into different equations to explain 
the release kinetics of FD release from transdermal patches [22]. The 
kinetic equations used zero-order and first-order equations. 
a)	 Zero-order	release	kinetics:	Defines	a	linear	relationship	between	
the fractions of drug released versus time
    Q=Kt
Where, Q is the fraction of drug released at time t 
K is the zero-order release rate constant 
b) First-order release kinetics: Wagner states that during dissolution 
process exposed surface area of formulation decreased exponentially 
with time, suggested that the drug release from slow release 
formulation	could	be	described	adequately	by	apparent	first-order	
kinetics.
	 	 	 	 (1−Q)=−	kt.
Models of drug release mechanism
The release data of transdermal patch were fitted into different 
mechanism models such as Higuchi model and Korsmeyer–Peppas 
model to interpret the drug release mechanism from patches. 
a) Higuchi (diffusion) model: It explains a linear dependence of the 
active fraction released per unit square (Q) on the square root of 
time. 
    Q=Kt½
b) Korsmeyer–Peppas model: A plot of the fraction of logarithm of the 
percentage of drug remained against time will be linear if the release 
obeys Korsmeyer–Peppas equation. 
    Log Q=log K + n log t
RESULTS AND DISCUSSION
Weight, thickness variation, drug content, and folding endurance
The physicochemical parameters such as weight variation, thickness 
variation, drug content, and folding endurance of the prepared 
transdermal patches are shown in Fig. 1 and Table 2. The range of 
weight the patches were from 118.2±3.06 to 123.9±2.82 mg and 
thickness ranges from 0.29±0.006 to 0.34±0.005 mm. When the content 
of HPMC E15 was increases in the patches, the weight and thickness of 
films are also increases. The results revealed that the transdermal films 
were uniform, as it was verified by relative standard deviation (RSD) 
value, which were <6. Observe the good uniformity in drug content in 
all transdermal patches as evidenced by low RSD values which were 
less than 1. The drug content ranges from 9.29±0.034 to 9.53±0.052 
mg. The folding endurance numbers of patch without permeation 
enhancer have in the range of 102.45±1.05 and for the films prepared 
with penetration enhancers were in the range of 114.33±2.08 to 
128.67±2.11. The number of folding endurance gives the mechanical 
property of the transdermal films; high folding endurance number 
indicates that the patches have high mechanical property. The results 
revealed that films would not break and would maintain their integrity 
when applied with general skin folding when applied.
Moisture absorption and moisture content studies
Moisture content and moisture absorption studies results are shown 
in Table 3. The moisture content in the patches varied from 1.649±2.34 
to 2.632±3.47. The moisture absorption in the patches was from 14.87 
±0.95% to 17.567±0.54%. The small moisture content in the patches 
helps them to remain stable and not being a completely dried and 
brittle film. Again, absorption of low moisture protects the transdermal 
patches from contamination with microbes.
Mechanical properties
The results of mechanical properties of tensile strength (TS) and 
elongation at break (E/B) are shown in Table 3. The mechanical 
properties show the patch strength and elasticity. It indicates that 
the polymer is soft and weak, when the values (TS and E/B) are low 
and polymer is hard and tough, when the values are high. Based on 
the all values obtained, patches having good mechanical property [6]. 
Optimized formulation F9 exhibited TS and E/B values (0.0942±0.0029 
kg/mm2 and 0.8749±0.054 mm2). Compare to all formulations, the 
optimized formulation F9 shows high TS and low E/B values that 
indicates F9 was found to be strong and flexible but not brittle.
In vitro drug release studies
The in vitro drug release profile of prepared transdermal patches is 
represented in Fig. 2. The setup of in vitro drug release studies shown in 
Fig. 3. The results of release studies showed that F2 formulation has drug 
release 8376.92±0.8 µg in 24 h. Hence, patches containing permeation 
enhancers F7, F8, and F9 showed higher drug release 9761.53±1.5 µg, 
10,038.46±1.4 µg, and 10,107.69±1.4 µgin 24 h, respectively, compared 
with formulation without enhancers. From the results and graphs, it is 
clear that the drug release from optimized formulation F9 containing 
lemongrass oil as a permeation enhancer showed higher drug release 
Fig. 1: Prepared transdermal formulations
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compare to all the formulations. The drug release was depends on 
polymer and permeation enhancer content. The data of in vitro release 
of all formulations well fitted into zero-order kinetics. 
Ex vivo permeation studies
Ex vivo permeation studies were carried out for F2, F7, F8, and F9 
formulations through pig ear skin because it was closest alternative to 
the human cadaver skin. The set up of ex vivo permeation studies shown 
in Fig. 4. The results shown in Fig. 5 reveal that F2 formulation has drug 
permeation 2556.76 µg and flux 19.2 µg/h/cm² earlier research studies 
revealed that menthol (F7), eucalyptus oil (F8), and lemongrass oil (F9) 
were used as permeation enhancers. To increase the drug permeation, 
permeation enhancers (F7, F8, and F9) in the concentration of 1% 
v/v were added to F2 formulation which showed a result of drug 
permeation F7 – 2866 µg, F8 – 3260.46 µg, and F9 – 3715.38 µg and 
flux F7 – 25.2 µg/h/cm², F8 – 27.9 µg/h/cm², and F9 – 35.2 µg/h/cm², 
respectively. Hence with the use of permeation, enhancer showed a 
good result in increase of drug permeation through pig ear skin. Plotting 
the cumulative amount of drug permeated per square centimeter 
against time in hours showed that the profile of drug permeation as it 
was proved by zero-order kinetics (r2=0.974) better fit than first-order 
kinetics (r²=0.931) and Korsmeyer-Peppas n value is 0.319. The r2 and 
n values reveal that the permeation of FD from the transdermal films 
followed zero-order and through anomalous mechanism.
Drug-polymer interaction studies
The FTIR (shown in Fig. 6) spectral analysis of FD alone showed that 
the principal peaks were observed at wave numbers of 3437.47 cm−1 
(N-H stretching), 1431.12 cm−1 (C-H stretching), and 1679.09 cm−1 (C=O 
stretching). The FTIR spectra of physical mixture of FD and HPMC E15 
approximate superimposition of drug and polymer FTIR spectra. These 
results suggest that there is no interaction between drug and polymer 
used in the present study. 
Table 2: Physicochemical evaluation of the transdermal patches
Formulation code Weight variation (mg) Thicknessᵃ (mm) Drug contentᵇ % Constrictionᵇ enduranceᵇ Folding 
F2 120.6±2.6 70.29±0.006 9.36±0.042 1.18±0.083 132.45±1.05
F7 118.2±3.06 0.32±0.010 9.53±0.052 2.08±0.011 114.33±2.08
F8 128.9±2.82 0.35±0.005 9.29±0.034 1.56±0.027 251.33±5.56
F9 119.1±3.24 0.49±0.006 9.47±0.039 1.88±0.036 104.67±4.11
aValues represent mean±6, bValues represent mean±3
Table 3: Moisture studies and mechanical properties of transdermal patches
Moisture studies mechanical properties 




F2 4.87±0.95 1.649±2.34 1.296×10ˉ⁴±0.028 0.0940±0.0022 1.4367±0.187
F7 6.233±0.23 2.103±2.87 0.653×10ˉ⁴±0.016 0.0793±0.0015 0.9974±0.108
F8 4.567±0.54 1.944±4.99 0.531×10ˉ⁴±0.029 0.0788±0.0024 1.1252±0.073
F9 5.992±0.59 2.632±3.47 0.782×10ˉ⁴±0.034 0.0652±0.0029 0.8749±0.054




























Fig. 2: In vitro drug release studies of transdermal patches. Values 
represent mean ± SD
Fig. 3: Paddle over disc method for drug release studies of 
transdermal patches
Fig. 4: (a) Pig ear skin, (b) separation of epidermis of pig ear skin, (c) arrangement of pig ear skin in Franz diffusion cell 
cba
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Fig. 5: Ex vivo drug permeation studies through pig ear skin. Values represent mean ± SD
Fig. 6: Drug-excipient interaction studies (FTIR). (a) Pure drug, (b) hydroxypropyl methylcellulose (HPMC) E15, (c) Eudragit RL PO, (d) 
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CONCLUSION
The present study showed that FD patch containing HPMC E15 and 
Eudragit RL PO in the ratio of 1:6 with 15%v/w of PEG 600 achieved the 
desired objectives of TDDS such as overcoming first-pass effect, thus 
increases the bioavailability of FD. The polymeric patches containing FD 
were evaluated for physicochemical, in vitro, and ex vivo characteristics. 
The formulation containing HPMC E15, Eudragit RL PO, and permeation 
enhancer (lemongrass oil 1%v/v) was found to increase higher flux 
35.2 µg/h/cm². The transdermal patches with required flux could be 
prepared with suitable mechanical properties.
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